Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Publication

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Journal Paper/Review - Feb 7, 2021

Ossenkoppele Gert, Pabst Thomas, Oosterveld Margriet, Obbergh Florence van, Nijziel Marten, Moors Ine, Kooy Marinus van Marwijk, Maertens Johan, Loosdrecht Arjan van de, Legdeur Marie-Cecile, Poel Marjolein van der, Sinnige Harm, Spertini Olivier, Norden Yvette van, Stussi Georg, Westerweel Peter, Weerdt Okke de, Vellenga Edo, Vekemans Marie-Christiane, Velden Walter van der, Tick Lidwine, Terpstra Wim, Lammeren-Venema Danielle van, Kuball Jurgen, Deeren Dries, Chalandon Yves, Brouwer Rolf, Breems Dimitri, Borne Peter von dem, Biemond Bart, Bargetzi Mario, Manz Markus, Löwenberg Bob, Efthymiou Anna, Gjertsen Bjørn-Tore, Graux Carlos, Klift Marjolein van der, Klein Saskia, Jongen-Lavrencic Mojca, Jie Asiong, Jaspers Aurelie, Hoogendoorn Mels, Hess Urs, Heim Dominik, Gregor Michael, Janssen Jeroen

Citation

Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel) 2021; 13

Type

Journal Paper/Review (English)

Journal

Cancers (Basel) 2021; 13

Publication Date

Feb 7, 2021

Issn Print

2072-6694

Brief description/objective

Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66-81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg ( = 116), days 1-21. In the second cycle, patients received cytarabine 1000 mg/m twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60-77%) vs 64% (55-73%), respectively). At 24 months, event-free survival (EFS) was 20% for the standard arm versus 12% for the tosedostat arm (Cox-p = 0.01) and overall survival (OS) 33% vs 18% respectively ( = 0.006). Infectious complications accounted for an increased early death rate in the tosedostat arm. Atrial fibrillation was more common in the tosedostat arm as well. The results of the present study show that the addition of tosedostat to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients.